FDA expands approved use of Imbruvica for rare form of non-Hodgkin lymphoma

The U.S. Food and Drug Administration today expanded the approved use of Imbruvica (ibrutinib) for previously treated patients with Waldenström’s macroglobulinemia (WM), a rare form of cancer that begins in the body’s immune system. The drug received a breakthrough therapy designation for this use.

http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm432123.htm

Source: Food and Drug Administration - January 29, 2015 Category: American Health Source Type: news